Comparison of Exacerbation Risk and Health Outcomes in Maintenance Treatment Naïve COPD patients using Stiolto vs. Trelegy

Study identification

• EU PAS number:
  EUPAS48472
• Study ID:
  48473
• Official title and acronym:
  Comparison of Exacerbation Risk and Health Outcomes in Maintenance Treatment Naïve COPD patients using Stiolto vs. Trelegy
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The purpose of this study was to investigate the risk of COPD exacerbations, community acquired pneumonia, and health care utilization and costs in maintenance treatment naïve patients following initiation of COPD therapy with Tiotropium/Olodaterol (TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Actual: 29/10/2020

Study start date

Actual: 17/12/2021

Date of final study report

Actual: 06/07/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable